Atea Pharmaceuticals, Inc. · NASDAQ:AVIR
Atea Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
22 slides from Atea Pharmaceuticals's conference presentation, January 2025
Slide 1: ATEA Corporate Presentation
ATEA Corporate Presentation January 2025
Slide 2: Disclaimers
DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our curr
Slide 3: Broad Antiviral Pipeline with De-risked Phase 3 Program
Broad Antiviral Pipeline with De-risked Phase 3 Program Program Therapeutic/ Indication Preclinical Phase 1 Phase 2 Phase 3 Upcoming Milestone End-of-Phase 2 meeting with Flaviviridae Hepatitis C FDA planned for January Fixed Dose Combination: 2025 Bemnifosbuvir (BEM) Nucleotide Phase 3 initiation p
Slide 4: BEM+RZR Regimen De-risked Phase 3 HCV Program for Multibillion-Dollar Market
BEM+RZR Regimen De-risked Phase 3 HCV Program for Multibillion-Dollar Market Ready for Potential Best-In- Robust Phase 2 Large Market Long Patent Commercial-scale Class Treatment Results Opportunity Life Manufacturing • Robust Phase 2 results for antiviral therapies have historically led to high pro
Slide 5: Global HCV: Large Market with Undertreatment of Infections
Global HCV: Large Market with Undertreatment of Infections WHO Worldwide Numbers 50 Million 1 Million Chronic HCV is Leading 242,000 People Infected1 New Infections Annually 1 Cause of Liver Cancer in US, Annual Deaths1 EU & Japan2 CDC US: 2.4 – 4 Million Untreated, >160K Newly Reported Annual Infec
Slide 6: US HCV: Major Commercial Opportunity Poised for Growth
US HCV: Major Commercial Opportunity Poised for Growth Attractive Near-Term Opportunity Poised for Growth >$20B+ Primarily 2 product No Potential US Market competitors in Opportunity2 market clinical development $3B $1.5B Potential US government global net sales US net sales initiatives to in 20231
Slide 7: 94% of US Prescribers Want Improvements to Current HCV Therapies
94% of US Prescribers Want Improvements to Current HCV Therapies HCV Prescribers and Patients Need Improved Therapy HCPs Report ~20% of Patients Are Not Unmet Needs from Physician Survey Compliant with DAA Therapy1 (N = 157 US Healthcare Providers) 2 51% 53% 19% Overall 17% Co-Infected HIV / HCV Pat
Slide 8: BEM+RZR: Potential Best-in-Class Profile
BEM+RZR: Potential Best-in-Class Profile • BEM+RZR: Next generation, pan-genotypic, fixed dose combination of BEM, most potent HCV nucleotide and RZR, highly potent HCV NS5A inhibitor • Targeted Indications: Treatment of adult patients 18 years+ with chronic HCV infection, with and without compensat
Slide 9: Drug-Drug Interaction Profile of BEM+RZR Regimen is a Key Differentiator
Drug-Drug Interaction Profile of BEM+RZR Regimen is a Key Differentiator for HCV Treatment -- ~80% of HCV Patients Take Concomitant Medications1 Healthcare Providers Prefer Therapies Convenient to Prescribe Drug BEM+RZR MAVYRET® EPCLUSA® Oral Contraceptives2 Protease Inhibitor-Containing HIV Drugs S
Slide 10: BEM+RZR Potential Best-in-Class Pan-Genotypic Regimen
BEM+RZR Potential Best-in-Class Pan-Genotypic Regimen Global Phase 2 Results Global Phase 3 Program 10
Slide 11: Phase 2 Open Label Study of BEM+RZR in HCV Patients (N=275)
Phase 2 Open Label Study of BEM+RZR in HCV Patients (N=275) Patient Population: HCV-infected patients BEM 550 mg QD including compensated cirrhosis, direct- acting antiviral naïve, all genotypes RZR 180 mg QD 8 weeks dosing w/combination Total Enrolled (N=275) Primary Endpoints: Per-Protocol Populat
Slide 12: Efficacy Primary Endpoint: High SVR12 Rates
Efficacy Primary Endpoint: High SVR12 Rates with 98% SVR12 95% SVR12 Regardless of Adherence Robust potency and drug Treatment viral kinetics in hard- forgiveness to-treat cirrhotic patients 100% 100% 98% 100% 95% 80% 80% 85% HCV RNA <LLOQ (%) 60% 60% SVR12 (%) 40% 40% 20% 20% 208/213 242/256 29/34
Slide 13: 99% SVR12 in Non-Cirrhotic Treatment Adherent Patients Across Genotypes
99% SVR12 in Non-Cirrhotic Treatment Adherent Patients Across Genotypes 97% SVR12 Regardless of Adherence Very high SVR12 cure rates in non-cirrhotic Robust potency and drug patients across genotypes forgiveness 100% 100% 99% 99% 100% 100% 100% Overall: 97% 98% 99% SVR12 97% SVR12 80% Non-cirrhotic
Slide 14: Safety Primary Endpoint: BEM+RZR Regimen Generally Safe and Well Tolerated
Safety Primary Endpoint: BEM+RZR Regimen Generally Safe and Well Tolerated Phase 2 Open Label Study of BEM+RZR for 8 Weeks End-of-Phase 2 meeting with US FDA planned for January 2025 to support global Phase 3 program No drug-related SAEs or Regimen was generally treatment AEs were generally mild No
Slide 15: Anticipated Global HCV Phase 3 Program
Anticipated* Global HCV Phase 3 Program 1 Trial US / Canada & 1 Trial Outside North America Open-label: BEM+RZR Regimen vs Active Comparator in Chronic HCV Patients Randomized (1:1) Non-Cirrhotic 8 weeks BEM+RZR FDC Chronic HCV, patients stratified by cirrhosis US / Canada Trial ~N=680 1:1 12 weeks
Slide 16: Prescriber & Payor Reaction to Profile
Potential Best-in-Class Pan-Genotypic Regimen Prescriber & Payor Reaction to Profile 16
Slide 17: Highly Positive Reaction to BEM+RZR Profile by US Prescribers
Highly Positive Reaction to BEM+RZR Profile by US Prescribers Majority of US healthcare providers indicate a high likelihood of prescribing BEM+RZR Regimen Overall Impression of BEM+RZR Profile Favorable 1 Positive Impression of BEM+RZR Profile Regardless of Specialty HEPs IDs GIs PCPs 89% Positive
Slide 18: Majority US Payors Receptive to Inclusion of BEM+RZR Regimen on Formulary
Majority US Payors Receptive to Inclusion of BEM+RZR Regimen on Formulary Payors covering >130M lives rated BEM+RZR profile either superior or comparable to Epclusa® or Mavyret® High willingness to add BEM+RZR regimen onto formulary Key insights regarding BEM+RZR 55% 53% regimen and payor access • M
Slide 19: BEM+RZR Regimen Has Potential to Become Most Prescribed Treatment
BEM+RZR Regimen Has Potential to Become Most Prescribed Treatment in Multibillion-Dollar HCV Market 3rd entrants with differentiated profile have been highly successful BEM+RZR Projected to be the Most Preferred DAA 1 3rd Entrants in Highly Entrenched Class with Limited EPCLUSA® MAVYRET® BEM+RZR Com
Slide 20: De-risked Phase 3 Program with Blockbuster Potential
De-risked Phase 3 Program with Blockbuster Potential 20
Slide 21: BEM+RZR Regimen De-Risked Phase 3 HCV Program for Multibillion-Dollar Market
BEM+RZR Regimen De-Risked Phase 3 HCV Program for Multibillion-Dollar Market Ready for Potential Best-In- Robust Phase 2 Large Market Long Patent Commercial-scale Class Treatment Results Opportunity Life Manufacturing Demonstrated very 98% cure rate after Fixed dose regimen >$3B global net Atea IP f
Slide 22: 225 Franklin Street, Boston MA
225 Franklin Street Suite 2100 Boston MA USA 02110 www.ateapharma.com 22
Atea Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix